Impact of Chemotherapy Dose Reductions on Survival Outcomes Among Older NSCLC Patients Without Actionable Mutations
Impact of Chemotherapy Dose Reductions on Survival Outcomes Among Older NSCLC Patients Without Actionable Mutations: A Retrospective Cohort Study.
University of Malaya
150 participants
Jan 1, 2026
OBSERVATIONAL
Conditions
Summary
Evidence suggests that appropriately selected older adults can tolerate standard-dose chemotherapy and achieve survival outcomes comparable to younger patients. However, older adults are usually under-represented in clinical trials and often receive reduced doses of chemotherapy due to concerns regarding age-related frailty, polypharmacy, and toxicity. This study seeks to evaluate chemotherapy dosing patterns and associated survival outcomes in older patients.
Eligibility
Inclusion Criteria4
- Age ≥65 years
- Histologically confirmed stage IV NSCLC
- Negative for EGFR mutation, ALK rearrangement, and ROS1 fusion
- Treated with at least ONE cycle of first-line chemotherapy
Exclusion Criteria2
- Patients who received targeted therapy or immunotherapy as monotherapy in the first-line setting
- Incomplete survival data
Interventions
PFS
OS
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07369596